JP2012509283A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509283A5
JP2012509283A5 JP2011536703A JP2011536703A JP2012509283A5 JP 2012509283 A5 JP2012509283 A5 JP 2012509283A5 JP 2011536703 A JP2011536703 A JP 2011536703A JP 2011536703 A JP2011536703 A JP 2011536703A JP 2012509283 A5 JP2012509283 A5 JP 2012509283A5
Authority
JP
Japan
Prior art keywords
cells
pancreatic
pharmaceutical composition
stro
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509283A (ja
JP5891034B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2009/001511 external-priority patent/WO2010057260A1/en
Publication of JP2012509283A publication Critical patent/JP2012509283A/ja
Publication of JP2012509283A5 publication Critical patent/JP2012509283A5/ja
Application granted granted Critical
Publication of JP5891034B2 publication Critical patent/JP5891034B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536703A 2008-11-20 2009-11-19 膵機能障害の治療または予防方法 Active JP5891034B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19979608P 2008-11-20 2008-11-20
US61/199,796 2008-11-20
PCT/AU2009/001511 WO2010057260A1 (en) 2008-11-20 2009-11-19 Method for treating or preventing a pancreatic dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015111995A Division JP6499016B2 (ja) 2008-11-20 2015-06-02 膵機能障害の治療または予防方法

Publications (3)

Publication Number Publication Date
JP2012509283A JP2012509283A (ja) 2012-04-19
JP2012509283A5 true JP2012509283A5 (https=) 2012-12-20
JP5891034B2 JP5891034B2 (ja) 2016-03-22

Family

ID=42197754

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2011536703A Active JP5891034B2 (ja) 2008-11-20 2009-11-19 膵機能障害の治療または予防方法
JP2015111995A Active JP6499016B2 (ja) 2008-11-20 2015-06-02 膵機能障害の治療または予防方法
JP2017112578A Withdrawn JP2017214384A (ja) 2008-11-20 2017-06-07 膵機能障害の治療または予防方法
JP2019162845A Active JP7051770B2 (ja) 2008-11-20 2019-09-06 膵機能障害の治療または予防方法
JP2021177234A Withdrawn JP2022031662A (ja) 2008-11-20 2021-10-29 膵機能障害の治療または予防方法
JP2023086994A Active JP7751607B2 (ja) 2008-11-20 2023-05-26 膵機能障害の治療または予防方法
JP2025099335A Pending JP2025148353A (ja) 2008-11-20 2025-06-13 膵機能障害の治療または予防方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2015111995A Active JP6499016B2 (ja) 2008-11-20 2015-06-02 膵機能障害の治療または予防方法
JP2017112578A Withdrawn JP2017214384A (ja) 2008-11-20 2017-06-07 膵機能障害の治療または予防方法
JP2019162845A Active JP7051770B2 (ja) 2008-11-20 2019-09-06 膵機能障害の治療または予防方法
JP2021177234A Withdrawn JP2022031662A (ja) 2008-11-20 2021-10-29 膵機能障害の治療または予防方法
JP2023086994A Active JP7751607B2 (ja) 2008-11-20 2023-05-26 膵機能障害の治療または予防方法
JP2025099335A Pending JP2025148353A (ja) 2008-11-20 2025-06-13 膵機能障害の治療または予防方法

Country Status (10)

Country Link
US (3) US8894972B2 (https=)
EP (2) EP2350266B1 (https=)
JP (7) JP5891034B2 (https=)
KR (2) KR102011609B1 (https=)
CN (3) CN102307992B (https=)
AU (1) AU2009317874B2 (https=)
CA (1) CA2744228C (https=)
DK (1) DK2350266T3 (https=)
ES (2) ES2550795T3 (https=)
WO (1) WO2010057260A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006168A1 (en) * 2006-07-12 2008-01-17 Angioblast Systems, Inc. Treatment of excessive neovascularization
ES2550795T3 (es) * 2008-11-20 2015-11-12 Mesoblast, Inc. Método para tratar o prevenir una disfunción pancreática
CN107149679B (zh) 2009-03-05 2021-03-02 哈佛学院董事会 分泌的aP2及其抑制方法
KR101891260B1 (ko) * 2010-07-02 2018-08-24 메소블라스트, 아이엔씨. T-세포 매개된 면역 질환의 치료
CN107638428B (zh) * 2011-05-19 2021-07-23 麦瑟布莱斯特公司 用于治疗肥胖症和/或代谢综合征的方法
AU2012262675B2 (en) * 2011-06-03 2016-05-19 Mesoblast, Inc Methods of treating or preventing neurological diseases
CA2839341C (en) * 2011-07-04 2020-12-15 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
CN104508124B (zh) 2011-07-06 2017-11-17 细胞治疗有限公司 中胚层谱系祖细胞
CN104098682B (zh) * 2013-04-03 2018-01-02 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN105358163B (zh) * 2012-12-12 2020-09-11 麦瑟布莱斯特公司 内皮功能障碍和炎症的疾病的治疗
US20140314872A1 (en) * 2013-04-22 2014-10-23 Hans Klingemann Methods of Use of Culture Supernatant Obtained from Mesenchymal Stem Cells from Dogs and Cats for Treatment of Organ Dysfunction
CN104714021B (zh) * 2013-12-12 2016-05-25 张曼 尿液凝血酶原蛋白在2型糖尿病合并冠心病中的应用
TW201702271A (zh) 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 治療代謝病症之抗-ap2抗體及抗原結合劑
BR112018076703A2 (pt) * 2016-06-27 2019-04-02 President And Fellows Of Harvard College compostos úteis para tratar distúrbios metabólicos
WO2018227200A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
CN110959579A (zh) * 2019-11-14 2020-04-07 顾隽 患者来源的淋巴瘤免疫缺陷小鼠移植瘤模型的构建方法及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
WO2004016747A2 (en) * 2002-08-14 2004-02-26 University Of Florida Bone marrow cell differentiation
US9631176B2 (en) * 2003-11-04 2017-04-25 Biomaster, Inc. Method for preparing stem cells from fat tissue
CN101506355B (zh) * 2004-09-24 2012-06-27 成血管细胞系统公司 多能扩增间充质前体细胞子代(memp)及其应用
CN101248171B (zh) * 2005-04-12 2015-11-25 迈索布拉斯特股份有限公司 通过组织非特异性碱性磷酸酶分离成人多潜能细胞
GB0514785D0 (en) * 2005-07-19 2005-08-24 Innovia Films Ltd Sealed ream wrap package and films suitable for forming such packages
AU2007243221A1 (en) * 2006-04-28 2007-11-08 Tulane University Health Sciences Center Methods for treating diabetes
AU2008210988B2 (en) * 2007-02-01 2012-09-06 Allocure, Inc. Potentiation of stem cell homing and treatment of organ dysfunction or organ failure
ES2550795T3 (es) 2008-11-20 2015-11-12 Mesoblast, Inc. Método para tratar o prevenir una disfunción pancreática
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit

Similar Documents

Publication Publication Date Title
JP2012509283A5 (https=)
JP7751607B2 (ja) 膵機能障害の治療または予防方法
Zhao et al. Drug delivery system in the treatment of diabetes mellitus
Zang et al. Mesenchymal stem cell therapy in type 2 diabetes mellitus
JP2017214384A5 (https=)
JP2022031662A5 (https=)
JP2006506386A5 (https=)
JP2006506386A (ja) 糖尿病の処置
US20140105861A1 (en) Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
WO2014075589A1 (zh) 一种间充质干细胞注射液及其制备方法和在制备治疗糖尿病药物中的应用
Muchmore et al. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase
CN102363633A (zh) 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
JP2016519127A (ja) 新規投与レジメン
CN106279400A (zh) P8降糖肽的设计及其用途
JP2020502140A5 (https=)
EP3142686A2 (fr) Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
Asaad et al. Exploring cutting-edge approaches in diabetes care: from nanotechnology to personalized therapeutics
Marques et al. GLP-1 analogue-loaded glucose-responsive nanoparticles as allies of stem cell therapies for the treatment of type I diabetes
JP6049625B2 (ja) 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US9914910B2 (en) Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1
US20200046700A1 (en) Focal adhesion kinase inhibitor as a therapeutic agent in diabetes
JP2007513059A5 (https=)
CN106074376A (zh) 一种胰高血糖素样肽‑1缓释纳米制剂、制备方法及应用
Krempf et al. Effect of long-acting somatostatin analog (SMS 201-995) on high glomerular filtration rate in insulin dependent diabetic patients.
George Future trends in diabetes management.